Intellia Therapeutics, Inc. (FRA:38I)

Market Cap	1.24B +20.9%
Revenue (ttm)	49.03M +33.5%
Net Income	-379.96M
EPS	-3.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	222
Open	10.82
Previous Close	10.94
Day's Range	10.82 - 10.82
52-Week Range	5.30 - 24.34
Beta	n/a
RSI	53.70
Earnings Date	Feb 26, 2026

About Intellia Therapeutics

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 403
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 38I

Financial Performance

In 2024, Intellia Therapeutics's revenue was $57.88 million, an increase of 59.55% compared to the previous year's $36.28 million. Losses were -$519.02 million, 7.86% more than in 2023.

Financial numbers in USD